Application of immunosuppressive agents in children with pediatric living-donor liver transplantation
- Author:
- No author available
- Journal Title:
- Chinese Journal of Organ Transplantation
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.0254-1785.2012.05.007
- Key Word:
- 肝移植;儿童,学龄前;活体供者;他克莫司;环孢菌素;Liver transplantation;Child,preschool;Living donors;Tacrolimus;Cyclosporine
Abstract： Objective To surnmarize the experience of tacrolimus or cyclosporine A-based immunosuppression after pediatric living-donor liver transplamation.Methods The clinical data of 30 children undergoing living-donor liver trarsplantation from October 2006 to January 2010 were analyzed retrospectively.In 30 patients,7 were given Tac-based immunosuppression (group A),10 given CsA-based immunosuppression (group B),and 13 switched from CsA to Tac for complications or adverse effects of drugs.Dosages and blood concentrations of immunosuppressants were recorded.Changes of liver and kidney functions were monitored.Incidence of rejection,infection and adverse effects of drugs were observed.Results In the premise of the stable concentration and liver and kidney functions,the weight of children was increased by about 50％ and the per- kilogram dosage of CNIs was decreased significantly 1year postoperatively.There was no case of rejection in group A and 4 cases of rejection in group B(40％,4/10),and the original symptoms were gradually alleviated after the increased dosage in immunosuppressants.During the first 3 months,there was 1case of abdominal infection in group A (1/7) and 3 cases of lung infection in group B (3/10),and the original symptoms were gradually alleviated after anti-infective therapy.There was 1CMV lgM-positive case in group A (1/7) and 2 CMV IgM-positive cases in group B (2/10),and the original symptoms were gradually alleviated after using ganciclovir.The original symptoms of the 13 children switched from CsA to Tac were gradually alleviated.Conclusion The two CNIs can be safely used in children undergoing pediatric livlng-donor liver transplantation.Both of them show the same effect in promoting the restoration of liver and kidney functions,but tacrolimus has more satisfactory effect in inhibiting the rejection and it has leas adverse effects.
- [1]汤晓寅,夏强,张建军,等.活体部分供肝移植术后他克莫司的用量及代谢特点[J].2010,(12).
- [2]夏强,张建军,李齐根,等.婴幼儿活体肝移植33例[J].2011,(1).
- [3]Turpin S,Alvarez F,Herzog D,etc.Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation.[J].2006,81(5).
- [4]McDiarmid SV,Lindblad AS,Anand R.Studies of Pediatric Liver Transplantation: 2002 update. An overview of demographics, indications, timing, and immunosuppressive practices in pediatric liver transplantation in the United States and Canada.[J].2004,8(3).
- [5]Atkison P,Martin SR,Lindblad AS,etc.Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada.[J].2004,8(3).
- [6]Prabhakaran K,Aw MM,Ariyarajah V,etc.Comparison between effects of cyclosporine and tacrolimus on glomerular filtration rate in pediatric post-orthotopic liver transplant patients.[J].2006,10(1).
- [7]Burdelski M,Ganschow R,Kemper MJ,etc.Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.[J].2006,10(8).
- [8]V, Furlan,D, Debray,C, Fourre,etc.Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation.[J].2000,4(3).
- [9]Gibelli NE,Tannuri U,Pinho Apezzato ML.Sirolimus in pediatric liver transplantation: a single-center experience.[J].2009,41(3).
- [10]Ekong UD,Bhagat H,Alonso EM.Once daily calcineurin inhibitor monotherapy in pediatric liver transplantation.[J].2010,10(4).
- [11]Mazariegos GV,Soltys KA,Sindhi RK,etc.Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database.[J].2007,7(9).
- [12]Berquist WE,Litt IF,Wayman KI,etc.Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients.[J].2008,12(2).
- [13]Cho CS,Manthei ER,Colburn M,etc.Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.[J].2003,15(11).
- [14]Shalev A,Nir A,Granot E.Cardiac function in children post-orthotopic liver transplantation: Echocardiographic parameters and biochemical markers of subclinical cardiovascular damage.[J].2005,9(6).
- [15]Dommergues JP,Letierce A,Gravereau L,etc.Current lifestyle of young adults after liver transplantation during childhood.[J].2010,10(7).
- [16]Dumont FJ.FK506, an immunosuppressant targeting calcineurin function.[J].2000,7(7).
- [17]Burdick J,Ascher NL,McDiarmid SV,etc.FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.[J].1995,59(4).
- [18]Dupuis RE,Gerber DA,Shrestha R,etc.Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients.[J].2002,8(3).
- [19]Kelly D.Safety and efficacy of tacrolimus in pediatric liver recipients.[J].2011,15(1).
- [20]Michael A. Heneghan,Markus Selzner,Eric M. Yoshida,etc.Pregnancy and sexual function in liver transplantation[J].2008,49(4).
- [21]Herrero, JI.De Novo Malignancies Following Liver Transplantation: Impact and Recommendations[J].2009,15(11S2).
- [22]Iwane T,Miyagi S,Satomi S,etc.Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy.[J].2009,41(1).